Abstracts tagged "Total joint replacement"

Abstract Number: 0552 • ACR Convergence 2022
Identifying Subgroups of Patients Undergoing Knee Replacement
Brooke McGinley¹, Gabriela Rabasa², Tuhina Neogi³, David Felson² and Michael LaValley⁴, ¹Boston University School of Public Health, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Boston University School of Public Health, Arlington, MA
Background/Purpose: Knee replacement surgery (KR) is prevalent in the US with estimated lifetime risk from age 25 of 7% for males and 9.5% for females,…
Abstract Number: 0837 • ACR Convergence 2022
Providers’ Adoption of 2017 Guidelines on DMARD Use Perioperatively for Elective Total Hip and Knee Arthroplasty at a Single Academic Center
Chris Ching¹, Erica Mulcaire-Jones², Andrew Shaffer¹, Jeremy Gililland¹, Michael Battistone³ and Dorota Lebiedz-Odrobina¹, ¹University of Utah, Salt Lake City, UT, ²Intermountain Healthcare, Salt Lake City, UT, ³Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Rate of prosthetic joint infection (PJI) after total joint arthroplasty (TJA) is higher in patients with rheumatic conditions than in patients with OA. Our…
Abstract Number: 0845 • ACR Convergence 2022
Predictors of Moderate-Vigorous Physical Activity Following a Physical Therapist Led Physical Activity Intervention for Adults with Total Knee Replacement
Scott Jamieson¹ and Christine Pellegrini², ¹The University of South Carolina, Arnold School of Public Health, Department of Exercise Science, Columbia, SC, ²University of South Carolina, Columbia, SC
Background/Purpose: Following total knee replacement rehabilitation, patients are advised to participate in physical activity. Yet, most individuals at this stage do not increase their physical…
Abstract Number: 0654 • ACR Convergence 2021
Assessing Provider Knowledge and Opinions of the 2017 Guidelines for Perioperative Management of Antirheumatic Medications in a Single Academic Center
Andrew Shaffer¹, Erica Mulcaire-Jones², Michael Battistone³, Jeremy Gililland⁴, Victor Carlson⁴, Joshua Zimmerman⁴, Kevin Lammert⁴ and Dorota Lebiedz-Odrobina⁴, ¹University of Utah, Sandy, UT, ²Intermountain Healthcare, Salt Lake City, UT, ³Salt Lake City VA, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT
Background/Purpose: Guidelines for perioperative management of antirheumatic medications were released by the American College of Rheumatology (ACR) and American Association of Hip and Knee Surgeons…
Abstract Number: 0727 • ACR Convergence 2021
Total Joint Replacements in Three Phase 3 Studies of Tanezumab in Patients with Osteoarthritis
John Carrino¹, Timothy McAlindon², Eric Vignon³, Mark Brown⁴, Aimee Burr⁴, Robert Fountaine⁴, Glenn Pixton⁵, Lars Viktrup⁶, Christine West⁴ and Kenneth Verburg⁴, ¹Hospital for Special Surgery, New York, NY, ²Tufts Medical Center, Arlington, MA, ³Université Claude Bernard Lyon 1, Lyon, France, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab (TNZ) is an antibody against nerve growth factor that has demonstrated efficacy in the management of osteoarthritis (OA). Due to the potential risk…
Abstract Number: 0734 • ACR Convergence 2021
Primary Total Knee Arthroplasty for Knee Osteoarthritis Among Younger versus Older Individuals: Cross-sectional Study of Surgical Appropriateness and Surgeon Decision-Making
Gillian Hawker¹, Eric Bohm², Michael Dunbar³, Allyson Jones⁴, Tom Noseworthy⁵ and Deborah Marshall⁵, ¹University of Toronto, Toronto, ON, Canada, ²Concordia Hip & Knee Institute, Winnipeg, MB, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Rising rates of total knee arthroplasty (TKA) in younger adults with knee osteoarthritis (OA) has prompted concern about surgical appropriateness. We compared patient appropriateness…
Abstract Number: 0735 • ACR Convergence 2021
Walking Ability 12 Months After Total Knee Arthroplasty for Osteoarthritis – Gap Between Expectations and Reality: The BEST Knee Cohort Study
Lauren King, Esther Waugh and Gillian Hawker, University of Toronto, Toronto, ON, Canada
Background/Purpose: Improved ability to walk is a key driver for people with knee osteoarthritis (OA) to seek total knee arthroplasty (TKA). However, the extent to…
Abstract Number: 0736 • ACR Convergence 2021
Decrease in Prevalence of Self-Reported Anxiety or Depression in Persons with Osteoarthritis After Total Knee Arthroplasty: The BEST KNEE Cohort Study
Owen Krystia, Lauren King, Esther Waugh and Gillian Hawker, University of Toronto, Toronto, ON, Canada
Background/Purpose: While anxiety and depression are highly prevalent in persons with symptomatic knee osteoarthritis (OA), few studies have assessed the effect of treatment of knee…
Abstract Number: 0755 • ACR Convergence 2021
Satisfaction with the Process versus Outcome of Care in Total Hip and Knee Arthroplasty
J. Alex Gibbons¹, Cynthia Kahlenberg¹, Bella Mehta², Vinicius Antao¹, Emily Ying Lai¹, Huong Do¹, Linda Russell¹, Peter Sculco¹, Mark Figgie¹ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Patient satisfaction, both with the process of care and the outcome of care, is critical for measuring the quality and value of elective procedures…
Abstract Number: 1037 • ACR Convergence 2021
Variations in Total Knee Replacement Utilization and Outcomes in USA and Canada: The Role of Geography and Socioeconomic Factors
Bella Mehta¹, Kaylee Ho², Vicki Ling³, Susan Goodman⁴, Michael Parks⁴, Bheeshma Ravi⁵, Samprit Banerjee², Said Ibrahim⁶ and Peter Cram⁷, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Hospital for Special Surgery, New York, NY, ⁵Sunnybrook Research Institute, Toronto, ON, Canada, ⁶Weill Cornell Medicine, Cleveland, OH, ⁷Sinai Health System and University Health Network, Toronto, ON, Canada
Background/Purpose: Total Knee Arthroplasty (TKA) is an effective treatment option for end-stage knee osteoarthritis. The US is well known for having striking wealth-based disparities in…
Abstract Number: 1051 • ACR Convergence 2021
Variance of Joint Space Width Across the Tibiofemoral Joint on Knee Radiographs: A Novel Measure of Structure and Progression
Kent Kwoh¹, Erin Ashbeck², Edward Bedrick¹, Xiaoxiao Sun¹ and Jeffrey Duryea³, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: The FDA accepts medial minimum joint space width (mJSW) in the tibiofemoral (TF) compartment as the standard for structural change in clinical trials of…
Abstract Number: 1129 • ACR Convergence 2021
Cost-effectiveness of Weight Loss Interventions Prior to Total Knee Replacement for Patients with Advanced Knee Osteoarthritis and Class III Obesity
Aleksandra Kostic¹, Valia Leifer², Tuhina Neogi³, David Hunter⁴, Lisa Suter⁵, Faith Selzer⁶, Jeffrey Katz¹ and Elena Losina⁷, ¹Brigham and Women's Hospital, Brookline, MA, ²The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Institute of Bone and Joint Research, University of Sydney, St Leonards, Australia, ⁵Yale School of Medicine, New Haven, CT, ⁶Brigham and Women's Hospital, Amesbury, MA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Class III obesity, defined by BMI >40kg/m2, is linked to increased risk of complications post total knee replacement (TKR). This has led to recommendations…
Abstract Number: 1447 • ACR Convergence 2021
Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement
S. Reza Jafarzadeh¹, Tuhina Neogi¹ and David Felson², ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are a primary treatment for osteoarthritis (OA). It is uncertain, however, whether regular use of NSAIDs affects the risk of…
Abstract Number: 1626 • ACR Convergence 2021
Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
J. Alex Gibbons¹, Cynthia Kahlenberg¹, Deanna Jannat-Khah¹, Susan Goodman¹, Lisa Mandl¹, Peter Sculco¹, Stuart Goodman², Mark Figgie¹ and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Stanford University, Stanford, CA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Total hip arthroplasty (THA) is a treatment option for young patients with severe hip pathology due to congenital, developmental, rheumatologic, traumatic, and other acquired…
Abstract Number: 1904 • ACR Convergence 2021
“Why Does My Knee Hurt After I Got My Knee Replaced?”: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement in Patients with Knee Osteoarthritis
Devin Driscoll¹, Priyanka Ballal¹, Na Wang², Laura Frey-Law³, Cora Lewis⁴, Michael Nevitt⁵ and Tuhina Neogi¹, ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA, ³University of Iowa, Iowa City, IA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵University of California San Francisco, Orinda, CA
Background/Purpose: Some people with knee osteoarthritis (OA) have persistent pain post-knee replacement, but why this occurs is not fully understood. One possibility is post-surgical neuropathy.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.